SCHEMBL16200819

SCHEMBL16200819

CC(C)(C)OC(=O)NC1CCN(Cc2ccc(Br)nc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.48
CACNA1I Q9P0X4 1/20 0.48
AKT1 P31749 1/20 0.48
KCNA3 P22001 1/20 0.48
CKS1B P61024 1/20 0.47
SKP1 P63208 1/20 0.47
SKP2 Q13309 1/20 0.47
NSD2 O96028 1/20 0.46
PARP1 P09874 1/20 0.45
PARP2 Q9UGN5 1/20 0.45
KMT2A Q03164 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
SIGMAR1 Q99720 2/20 0.44
DRD2 P14416 2/20 0.44
CCR5 P51681 1/20 0.43
MEN1 O00255 1/20 0.43
NAMPT P43490 1/20 0.42
NPY5R Q15761 1/20 0.42
PRKAB2 O43741 1/20 0.42
PRKAG1 P54619 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30135707 0.83 KCNA3 (0.52) AKT1KCNA3PARP1PARP2KMT2A
SCHEMBL29260128 0.82 KCNA3 (0.53) AKT1KCNA3PARP1PARP2KMT2A
SCHEMBL15021069 0.82 SIGMAR1 (0.59) AKT1KCNA3PARP1PARP2KMT2A
SCHEMBL27226915 0.82 SIGMAR1 (0.59) AKT1KCNA3PARP1PARP2KMT2A
SCHEMBL15021685 0.81 SIGMAR1 (0.60) AKT1KCNA3PARP1PARP2KMT2A
SCHEMBL648348 0.81 SIGMAR1 (0.60) AKT1KCNA3NSD2PARP1PARP2
SCHEMBL3351581 0.81 SIGMAR1 (0.60) KCNA3PARP1PARP2SIGMAR1PRKAA2
SCHEMBL915402 0.80 KMT2A (0.65) KCNA3KMT2AL3MBTL1SIGMAR1DRD2
SCHEMBL7475783 0.80 SIGMAR1 (0.65) KCNA3KMT2ASIGMAR1MEN1
SCHEMBL12011087 0.80 KMT2A (0.57) AKT1KCNA3PARP1PARP2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2991981-B1 DIAMINOPYRAZINE COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF BOEHRINGER INGELHEIM INT (DE) 2017-03-01 EP disclosed
US-9018215-B2 Heteroaromatic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-28 US disclosed
US-9018215-B2 Heteroaromatic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-28 US disclosed
WO-2014177469-A1 DIAMINOPYRAZINE COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH,M (DE) 2014-11-06 WO disclosed
US-20140323447-A1 HETEROAROMATIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-10-30 US disclosed
US-20140323447-A1 HETEROAROMATIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323447-A1 HETEROAROMATIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF SCNN1B, SCNN1A, SCNN1G KCNH2 135/4885CACNA1I 47/4885AKT1 4421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.